+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Senile and presenile cataract therapy with bendazac lysine a clinical evaluation



Senile and presenile cataract therapy with bendazac lysine a clinical evaluation



Bollettino di Oculistica 65(4): 671-684



An oral dose of 1500 mg/day of Bendazac-Lysine was administered to 32 patients affected by senile and presenile cataract, during a period of 9 months. Periodical controls of the visual acuity and biomicroscopical evaluation of lens opacities modifications, showed a mild improvement in 4 cases, worsening in 6 cases, while 22 patients did not show any significant change. The mechanism of the drug activity is probably a direct protection against lens proteins denaturation and an indirect one is on serum factors controlling denaturations of lens proteins.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 006387733

Download citation: RISBibTeXText


Related references

Clinical evaluation of topical bendazac lysine in treatment of senile cataract. Bollettino di Oculistica 67(1): 25-30, 1988

Controlled clinical evaluation of bendazac lysine in senile cataract a multicenter study analysis of the effects of 6 months treatment. Bollettino di Oculistica 64(1-2): 71-88, 1985

Medical treatment of senile cataract: clinical investigation of bendazac-lysine using objective and subjective methods. Graefe's Archive for Clinical and Experimental Ophthalmology 228(2): 105-111, 1990

Medical therapy of presenile and senile cataract clinical evaluation of bendazaclysine eye drops. Bollettino di Oculistica 69(1): 39-48, 1990

Bendazac Lysine in Selected Types of Human Senile Cataract. Ophthalmic Research 21(3): 141-154, 1989

Bendazac lysine in selected types of human senile cataract. A long-term double-masked placebo-controlled clinical trial with multilinear densitometric image analysis of Scheimpflug photographs. Ophthalmic Research 21(3): 141-154, 1989

New methods for studying lens opacities results of a double blind pilot study on the effect of bendazac lysine in senile cataract. Annali di Ottalmologia e Clinica Oculistica 111(12): 1085-1102, 1985

Critical evaluation of bendazac lysine salt in the treatment of cataract. Bollettino di Oculistica 63(11-12): 1271-1282, 1984

Clinical trial of bendazac lysine eye drops in the medical treatment of cataract. Bollettino di Oculistica 68(5): 823-834, 1989

Morbidity and risk factors in presenile cataract. I. Is senile cataract becoming less senile?. Revista de Chirurgie Oncologie Radiologie O. R. L. Oftalmologie Stomatologie. Seria: Oftalmologie 24(2): 115-119, 1980

Evaluation of effectiveness of Catalin eyedrops in patients with presenile and senile cataract. Klinika Oczna 106(6): 778-782, 2004

Mean age of patients with senile and presenile cataract in clinical material from 1987-1992. Klinika Oczna 95(7): 277-280, 1993

Evaluation of gk activity in red blood cells of patients with presenile and senile idiopathic cataract preliminary study. Bollettino Societa Italiana Biologia Sperimentale 66(9): 887-892, 1990

Senile and presenile cataract: Survey of patients undergoing cataract surgery. Acta Ophthalmologica 72(5): 602-605, 1994

Basic data supporting the use of the l-lysine salt of bendazac in cataract. International Journal of Tissue Reactions 5(2): 217-225, 1983